Nitroimidazoles: A newer class of Heterocycles for treatment of Tuberculosis

Nadim Chhipa; Pinkal Patel; Neil Panchal; Rakesh Parmar

doi:10.5958/0974-360X.2020.00609.5

Research Journal of Pharmacy and Technology

ISSN

0974-360X (Online)
0974-3618 (Print)

Submit Article

Nitroimidazoles: A newer class of Heterocycles for treatment of Tuberculosis

Author(s): Nadim Chhipa, Pinkal Patel, Neil Panchal, Rakesh Parmar

Email(s): chhipa.nadim7@gmail.com

DOI: 10.5958/0974-360X.2020.00609.5

Address: Nadim Chhipa1*, Pinkal Patel1, Neil Panchal1, Rakesh Parmar2
1Department of Pharmaceutical Chemistry, Parul Institute of Pharmacy and Research, Parul University, Limda, Tal-Whagodia - 391760, Vadodara, Gujarat, India.
2Department of Pharmaceutics, Parul Institute of Pharmacy and Research, Parul University, Limda, Tal-Whagodia-391760, Vadodara, Gujarat, India.
*Corresponding Author

Published In: Volume - 13, Issue - 7, Year - 2020

View HTML

View PDF

ABSTRACT:
The major cause of tuberculosis (TB) is infection of M. tuberculosis. Tuberculosis Reemerged as a major health concern and ranked among the Top 10 causes of deaths worldwide since 2000. Current TB therapies take too long and the regimens are complex and subject to adverse effects and drug–drug interactions with concomitant medications. Mainly interactions of the current TB drugs with the ARVs taken by HIV positive people, with increased number of multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains, and the ineffectiveness of the current treatment against latent TB are challenges to be overcome in the coming years. Nitroimidazole class of drugs is showing great activity against protozoal infection. In the current review, 5-nitroimidazole class of drugs becomes the potential candidate for to be discovered as anti-bacterial and antiprotozoal drugs. This review is about Nitroimidazole class, mainly four agents shown the potential anti-TB property, CGI-17341, PA-824, TBA-354 and OPC-67683. They have shown potent anti-TB activity by mixed effect both on genes responsive to cell wall inhibition (like isoniazid) and respiratory poisoning (like cyanide).

Keywords:

Cite this article:
Nadim Chhipa, Pinkal Patel, Neil Panchal, Rakesh Parmar. Nitroimidazoles: A newer class of Heterocycles for treatment of Tuberculosis. Research J. Pharm. and Tech. 2020; 13(7): 3425-3432. doi: 10.5958/0974-360X.2020.00609.5

Cite(Electronic):
Nadim Chhipa, Pinkal Patel, Neil Panchal, Rakesh Parmar. Nitroimidazoles: A newer class of Heterocycles for treatment of Tuberculosis. Research J. Pharm. and Tech. 2020; 13(7): 3425-3432. doi: 10.5958/0974-360X.2020.00609.5 Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-7-69

REFERENCE:

1. Nancy AK. Tuberculosis: Pathophysiology, Clinical features and diagnosis. Critical care nurse. 2009;29(2):34-43.

2. World Health organization (WHO) [Internet]. Tuberculosis: Factsheets; 2018 [cited 2019 May 3]. Available from: https:// www.who.int/news-room/ fact-sheets/detail/tuberculosis.

3. Sagavkar Sandhyarani R, Devkar Swati R. Tuberculosis: A Review. Asian Journal of Pharmaceutical Research. 2018; 8(3): 191-194.

4. Lalit K, Rajan, Vivek S. Tuberculosis: A Brief Overview Asian Journal of Pharmaceutical Research. 2012; 2(2): 59-62.

5. Lamees M. Immunological and Biochemical Changes Related of Tuberculosis in Human. Research Journal of Pharmacy and Technology. 2019; 12(7): 3428-3430.

6. Uma S, Swarna Latha S, Arun Satyadev S, Neelima P. Influence of HIV, Malnutrition and Patient Non-Compliance on the Prevalence and Prognosis of Tuberculosis: A Fatal Infectious Disease. Research Journal of Pharmacy and Technology. 2015; 8(10): 1365-1368.

7. Sandip Z, Shweta AP, Sushmita SR. Rise of Antibiotic Resistance in Tuberculosis. Research Journal of Pharmacy and Technology. 2018; 11(7): 3201-3204.

8. Syed Safiullah G, Mohammed Abdul Q, Hafsa Khalid. A Clinical Study of Acute Kidney Injury on using Antituberculosis Drugs in Geriatrics. Research J. Pharm. and Tech. 2017; 10(6): 1746-1750.

9. World Health organization (WHO) [Internet]. Percentage of New cases with MDR/RR TB; 2018 [cited 2019 May 3]. Available from: http://gamapserver.who.int/ map Library/ app/ searchResults.aspx.

10. Islam MM, Adnan HM, Mugweru J, Chhotaray C, Wang C, Tan Y, et al. Drug Resistance Mechanism and Novel Drug targets for tuberculosis therapy. Journal of Gene and Genom. 2017; 44:21-37.

11. Subramaniam S, Sangeetha D. Identification of New Inhibitor against Mycobacterium tuberculosis using structure based Drug Designing and Docking Studies. Research Journal of Pharmacognosy and Phytochemistry. 2017; 9(3): 173-176.

12. Prafulla S, Dhiraj B, Vidya S. Synthesis and Anti-Tubercular Activity of Substituted Phenylpyrazole having Benzimidazole Ring. Research Journal of Pharmacy and Technology. 2018; 11(8): 3599-3608.

13. Kwonjune JS, Salmaan K, Michael LR. Multidrug Resistance Tuberculosis and Extensive Drug Resistance Tuberculosis. Cold Spring Hrab Perspect Med. 2015; 5:1-20.

14. Aejaz A, Khurshid IM, Gulam JK. Synthesis, characterization and anti-inflammatory activity some 1-(4- substituted)-2-(-4-(piperazine-1-yl) bis-thiazole-5-yl) 2-methyl-4-nitro-1himidazole- 1-yl) ethanone. Asian Journal of Research in Chemistry. 2017; 10(2): 158-165.

15. Shaikh AA, Raguwanshi MG. Synthesis, Characterization of Some Novel Schiff’s bases of 4-((2-methyl- 4/5-nitro-1H-imidazol-1-yl) methyl) thiazol-2-amine and their Antimicrobial Activity. Asian Journal of Research in Chemistry. 2016; 9(11): 578-596.

16. Alka M. Synthetic NItroimidazoles: Biological activity and Mutagenesity Relationships. Scientia Pharmaceutica. 2009; 77:497-520.

17. Cavalleri B, Volpe G, Arioli V, Parenti F. Synthesis and biological activity of some 2- aminoimidazoles. Arzneimittelforschung. 1977;27(10):1889–95.

18. Schmid A, Schmid H. Pharmaco-toxicological mode of action of antimicrobial 5-nitroimidazole derivatives. Zentralbl Veterinarmed A. 1999;46(9):517–22.

19. Stover CK. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. 2000;405(6789):962-6.

20. Nagarajan, K, Shankar RG, Rajappa S, Shenoy SJ, Costa- Pereira R. Nitroimidazoles XXI 2,3-Dihydro-6-nitroimidazo[2,1-b]- oxazoles with Antitubercular Activity. European Journal of Medicinal Chemistry. 1989; 24:631-3.

21. MedKoo Bioscience, Inc. [Internet]. United States. CGI-17341, Product information; 2019 [cited 2019 May 4]. Available from: https://medkoo.com/products/14132.

22. Tathagata M, Helana B. Nitroimidazole for treatment of TB: Past, present and future. Future Medicinal Chemistry. 2011;3(11):1427-54.

23. Ashtekar DR, Costa-perira R, Nagrajan K, Vishwanatham M, Bhatt AD, Rittel W. In Vitro and In Vivo activities of Nitroimidazole CGI 17341 against Mycobacterium. Tuberculosis. 1993;37(2):183-6.

24. Strover CK, Warrener P, VanDeventer DR, Sherman DR, Arain TM, Langhorem MH, et al. A small molecule. Letters to Nature 2000; 405:962-6.

25. Hirofuni S, Yoshikazu S, Motohiro I, Hidekai K, Hiroyuki H, Tatsuo T, et al. Synthesis and Antituberculosis Activity of a Novel Series of Optically Active 6-Nitro-2,3-dihydroimidazo[2,1-b]oxazoles. Journal of Medicinal Chemistry. 2006; 49:7854-60.

26. Ujjini HM, Helena B, Cynthia SD, Liang Z, Thomas JA, Jason EN, et al. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. PNAS. 2006;103(2):431-6.

27. Adis Insight. [Internet]. Springer Publication. TBA-354, Drug Profile; 2019 [cited 2019 May 8]. Available from: https://adisinsight.springer.com/drugs/800042070.

28. Stop TB Partnership. [Internet]. Geneva. Working group on new TB drugs, TBA-354; 2019 [cited 2019 May 8]. Available from: https://www.newtbdrugs.org/pipeline/compound/tba-354.

29. Kmentova I, Sutherland HS, Palmer BD, Blaser A, Franzblau SG, Wan B, et al. Synthesis and Structure– Activity Relationships of Aza- and Diazabiphenyl Analogues of the Antitubercular Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6, 7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). Journal of Medicinal Chemistry. 2010;53: 8421-39.

30. Tanseen R, Williams K, Amoabeng O, Minkowsi A, Mdluli KE, Upton AM, et al. Contribution of the Nitroimidazoles PA-824 and TBA-354 to the Activity of Novel Regimens in Murine Models of Tuberculosis. Antimicrobial Agents and Chemotherapy. 2015; 59:129-35.

31. Upton AM, Cho S, Kim Y, Yang JT, Wang Y, Lu Y, et al.In Vitro and In Vivo Activities of the Nitroimidazole TBA-354 againsT Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2015; 59:136-44.

32. U.S. National Library of Medicine. [Internet]. Unites States. A phase 1 study to evaluate the Safety, Tolerability and Pharmacokinetics of TBA-354 in Healthy adult Subjects; 2019 [cited 2019 May 9]. Available from: https://clinicaltrials.gov/ct2/ show/ study/ NCT02288481.

33. TB Alliance. [Internet]. New York. Phase 1 Clinical trial of drug candidate TBA-354 discontinued; 2019 [cited 2019 May 9]. Available from: https://www.tballiance.org/news/phase-1-clinical-trial-tb-drug-candidate-tba-354-discontinued

34. Ntshangase S, Shobo A, Kruger HG, Asperger A, Niemeyer D, Arvidsson PI, et al. The downfall of TBA-354 – a possible explanation for its neurotoxicity via mass spectrometric imaging. Xenobiotica. 2017;48(9):938-44.

35. Adis Insight. [Internet]. Springer. Pretomanid – Global Alliance for TB Drug development, Drug Profile; 2019 [cited 2019 May 11]. Available from: https://adisinsight.springer.com/drugs/ 800007841.

36. TB Alliance. [Internet]. New York. TB Medicine Pretomanid Enters Regulatory review process In the United States; 2019 [cited 2019 May 11]. Available from: https://www.tballiance.org/news/ pretomanid-enters-FDA-review.

37. TB Alliance. [Internet]. New York. PA-824 has a new generic name: Pretomanid, Press release; 2019 [cited 2019 May 11]. Available from: https://www.tballiance.org/news/pa-824-has-new-generic-name-pretomanid.

38. Stop TB Partnership. [Internet] Geneva. Pretomanid. Working group on new TB drugs; 2019 [cited 2019 May 11]. Available from: https://www.newtbdrugs.org/pipeline/compound/ pretomanid.

39. Patel RV, Keum Y, Park SV. Nitroimidazoles, Quinolones and Oxazolidinones as Fluorine Bearing Antitubercular Clinical Candidates. Mini Reviews in Medicinal Chemistry. 2015;15(14):1174-86.

40. PA-824. Tuberculosis. 2008;88(2):134-6.

41. Kim P, Zhang L, Manjunatha UH, Singh R, Patel S, Jiricek J, et al. Structure-activity relationships of antitubercular nitroimidazoles. I. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles. Journal of Medicinal Chemistry. 2009;52(5):1317-28.

42. Manjunatha UH, Boshoff, HI, Bary III CE. The Mechanism of action of PA-824. Community Integral Biology. 2009;2(3):215-8.

43. Thompson AM, Blaser A, Anderson RF, Shinde SS, Franzblau SG, Ma Z, et al. Synthesis, Reduction Potentials, and Antitubercular Activity of Ring A/B Analogues of the Bioreductive Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). Journal of Medicinal Chemistry. 2009; 52:637-45.

44. Somasundaram S, Anand RA, Venkatesan P, Pramsivan CN. Bactericidal activity of PA-824 against Mycobacterium tuberculosis under anaerobic conditions and computational analysis of its novel analogues against mutant Ddn receptor. BMC microbiology. 2013; 13:218.

45. Rakesh P, Bruhm DF, Scherman MS, Singh AP, Yang L, Liu J, et al. Synthesis and evaluation of Pretomanid (PA-824) oxazolidinone hybrids. Bioorganic and Medicinal Chemistry Letters. 2016;26(2):388-91.

46. Thompson AM, Bonnet M, Lee HH, Franzblau SG, Wan B, Wong GS, et al. Antitubercular Nitroimidazoles Revisited: Synthesis and Activity of the Authentic 3‑Nitro Isomer of Pretomanid. ACS Medicinal Chemistry Letters. 2017;8: 1275-80.

47. Stop TB Partnership. [Internet]. Geneva. Delamanid. Working group on new TB drugs; 2019 [cited 2019 May 13]. Available from: https://www.newtbdrugs.org/pipeline/compound/delamanid-0.

48. TB Online. [Internet]. Global TB Community Advisory Board. OPC-67683 by Joan Leavens; 2019 [cited 2019 May 13]. Available from: http://www.tbonline.info/posts/2011/9/15/ opc67683/.

49. National Library of Medicine. [Internet]. United States. Safety, Efficacy and Pharmacokinetics of OPC-67683 in patients with pulmonary tuberculosis; 2019 [cited 2019 May 13]. Available From: https://clinicaltrials.gov/ct2/show/NCT00401271.

50. Stop TB Partnership. [Internet]. Geneva. News Stories; 2016 [cited 2019 May 13]. Available from: http://www.stoptb.org/news/ stories/2016/ ns16_005.asp#.

51. Showalter HD, Denny WA. A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment. Tuberculosis. 2008;88(Suppl-1): S3-S17.

52. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, et al. OPC- 67683, a nitro-dihydroimidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Medicine. 2006;3(11):2131-44.

53. Saliu OY, Crismale C, Schwander SK, Wallis RS. Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosis. Journal Antimicrobial and Chemotherapy. 2007; 60:994–8.

54. Diacon AH, Dawson R, Hanekom M, Narunsky K, Venter A, Hittel N, et al.Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. International Journal of Tubeculosis and Lung Diseases. 2011;15(7):949–54.

55. Gler MT, Skripconoka V, Sanchez-Gravito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE. Delamanid for Multidrug-Resistant Pulmonary Tuberculosis. New England Journal of Medicine. 2012;366(23):2151-60.

56. Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. European Respiratory Journal. 2013;41(6):1393-1400.

57. Caminero JA, Scardigli A. Classification of antituberculosis drugs: a new proposal based on the most recent evidence. European Respiratory Journal. 2015; 46:887-93.

58. Sotgui G, Pontali E, Centis R, D’Ambrosio L, Battista G, Migliori. Delamanid (OPC-67683) for treatment of multi-drug-resistance tuberculosis. Expert Reviews in AntiInfection Therapy. 2015;13(3):305–15.

59. Stinson K, Kurepina N, Venter A, Fujiwara M, Kawasaki M, Timm J, et al.MIC of Delamanid (OPC-67683) against Mycobacterium tuberculosis Clinical Isolates and a Proposed Critical Concentration. Antimicrobial agents and Chemotherapy. 2016;60(6):3316-22.